hydroxyurea has been researched along with Cerebral Infarction in 13 studies
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-Lipoxygenase inhibitor zileuton has been demonstrated to attenuate ischemic brain damage in rats of permanent focal cerebral ischemia in previous work." | 7.76 | Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. ( Chen, CM; Jin, CD; Shi, SS; Tu, XK; Wang, CH; Wen, S; Yang, WZ; Yang, YK; Zhang, YL, 2010) |
| "Bone marrow suppression medications (oral hydroxyurea and subcutaneous injection of interferon) were given and subsequent prevention of cerebral infarction was implemented." | 3.88 | A case report of cerebral infarction caused by polycythemia vera. ( Chen, Z; Gao, F; Ren, S; Wang, Z, 2018) |
| "5-Lipoxygenase inhibitor zileuton has been demonstrated to attenuate ischemic brain damage in rats of permanent focal cerebral ischemia in previous work." | 3.76 | Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. ( Chen, CM; Jin, CD; Shi, SS; Tu, XK; Wang, CH; Wen, S; Yang, WZ; Yang, YK; Zhang, YL, 2010) |
| "Children with preexisting silent cerebral infarcts receiving blood transfusions had lower hospitalization costs but higher outpatient costs, primarily associated with the oral iron chelator deferasirox." | 3.01 | Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial. ( Cronin, RM; DeBaun, MR; Gay, JC; Hsu, P; Lin, CJ; Rodeghier, M, 2021) |
| "Stroke is a significant cause of morbidity and mortality in children and adults with sickle cell disease." | 2.49 | Stroke in patients with sickle cell disease. ( Kwiatkowski, JL; Webb, J, 2013) |
| "Cerebral vasculopathy in sickle cell anemia (HbSS) is manifest clinically as cerebral infarction and intracranial hemorrhage." | 2.44 | Overt and incomplete (silent) cerebral infarction in sickle cell anemia: diagnosis and management. ( Powars, DR; Wong, WY, 2007) |
| "Treatment with hydroxyurea and CTT were obtained from the chart review." | 1.72 | Evolution of Extracranial Internal Carotid Artery Disease in Children With Sickle Cell Anemia. ( Alison, M; Balandra, S; Belarbi, N; Bernaudin, F; Cussenot, I; Elmaleh, M; Ithier, G; Kheniche, A; Ntorkou, A; Oloukoi, C; Ouaziz, H; Sekkal, A; Tanase, A; Verlhac, S, 2022) |
| "Stroke is a common cause of morbidity and mortality in sickle cell disease (SCD) and silent cerebral infarction is the most common form of neurologic injury." | 1.39 | Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. ( Calvaruso, G; Iannello, S; Maggio, A; Pecoraro, A; Rigano, P; Steinberg, MH, 2013) |
| "Previous thrombosis is an established risk factor for rethrombosis in patients with ET." | 1.38 | Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia. ( Cho, KH; Kim, KT; Sohn, SI, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, P | 1 |
| Gay, JC | 1 |
| Lin, CJ | 1 |
| Rodeghier, M | 1 |
| DeBaun, MR | 1 |
| Cronin, RM | 1 |
| Verlhac, S | 1 |
| Ithier, G | 1 |
| Bernaudin, F | 1 |
| Oloukoi, C | 1 |
| Cussenot, I | 1 |
| Balandra, S | 1 |
| Kheniche, A | 1 |
| Ntorkou, A | 1 |
| Ouaziz, H | 1 |
| Tanase, A | 1 |
| Sekkal, A | 1 |
| Belarbi, N | 1 |
| Elmaleh, M | 1 |
| Alison, M | 1 |
| Runge, A | 1 |
| Brazel, D | 1 |
| Pakbaz, Z | 1 |
| Oguro, H | 1 |
| Takahashi, T | 1 |
| Ren, S | 1 |
| Gao, F | 1 |
| Chen, Z | 1 |
| Wang, Z | 1 |
| Webb, J | 1 |
| Kwiatkowski, JL | 1 |
| Rigano, P | 1 |
| Pecoraro, A | 1 |
| Calvaruso, G | 1 |
| Steinberg, MH | 1 |
| Iannello, S | 1 |
| Maggio, A | 1 |
| Rushton, T | 1 |
| Aban, I | 1 |
| Young, D | 1 |
| Howard, T | 1 |
| Hilliard, L | 1 |
| Lebensburger, J | 1 |
| Tu, XK | 1 |
| Yang, WZ | 1 |
| Wang, CH | 1 |
| Shi, SS | 1 |
| Zhang, YL | 1 |
| Chen, CM | 1 |
| Yang, YK | 1 |
| Jin, CD | 1 |
| Wen, S | 1 |
| Kim, KT | 1 |
| Sohn, SI | 1 |
| Cho, KH | 1 |
| Brousse, V | 1 |
| Gandhi, S | 1 |
| de Montalembert, M | 1 |
| Height, S | 1 |
| Dick, MC | 1 |
| O'Driscoll, S | 1 |
| Abihsera, G | 1 |
| Rees, DC | 1 |
| Wong, WY | 2 |
| Powars, DR | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial[NCT00072761] | Phase 3 | 196 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI. (NCT00072761)
Timeframe: From study entry to study exit
| Intervention | infarct recurrence per 100 person years (Number) |
|---|---|
| Transfusion Group | 2.0 |
| Observation Group | 4.8 |
5 reviews available for hydroxyurea and Cerebral Infarction
| Article | Year |
|---|---|
Stroke in sickle cell disease and the promise of recent disease modifying agents.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Hydroxyurea; Strok | 2022 |
Stroke in patients with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Vessels; Brain; Cerebral Infarction; Humans; Hydroxy | 2013 |
Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference.
Topics: Cerebral Infarction; Female; Humans; Hydroxyurea; Male; Patient Preference | 2018 |
Overt and incomplete (silent) cerebral infarction in sickle cell anemia: diagnosis and management.
Topics: Age Factors; Anemia, Sickle Cell; Blood Transfusion; Cerebral Infarction; Humans; Hydroxyurea; Risk | 2005 |
Overt and incomplete (silent) cerebral infarction in sickle cell anemia: diagnosis and management.
Topics: Anemia, Sickle Cell; Blood Transfusion; Cerebral Infarction; Humans; Hydroxyurea | 2007 |
1 trial available for hydroxyurea and Cerebral Infarction
| Article | Year |
|---|---|
Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial.
Topics: Blood Transfusion; Cerebral Infarction; Child; Cost-Benefit Analysis; Humans; Hydroxyurea; Stroke; U | 2021 |
7 other studies available for hydroxyurea and Cerebral Infarction
| Article | Year |
|---|---|
Evolution of Extracranial Internal Carotid Artery Disease in Children With Sickle Cell Anemia.
Topics: Anemia, Sickle Cell; Carotid Artery Diseases; Carotid Artery, Internal; Carotid Stenosis; Cerebral I | 2022 |
[A case of recurrent non embolic stroke with non-fluent aphasia due to polycythemia vera].
Topics: Aged; Aphasia; Cerebral Infarction; Female; Humans; Hydroxyurea; Polycythemia Vera; Stroke | 2023 |
A case report of cerebral infarction caused by polycythemia vera.
Topics: Cerebral Infarction; Female; Humans; Hydroxyurea; Interferons; Middle Aged; Polycythemia Vera | 2018 |
Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Topics: Adult; Aged; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Cerebral Infarction; Cerebr | 2013 |
Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Brain; Brain Ischemia; Cerebral Infarction; Di | 2010 |
Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Biopsy; Bone Marrow Examination; Cerebral Angiography; Cerebral Infarct | 2012 |
Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Brain Ischemia; Cerebral Infarction; Cerebral Re | 2013 |